Darius Kharabi - 04 Jan 2023 Form 4 Insider Report for Kala Pharmaceuticals, Inc. (KALA)

Signature
/s/ Eric Trachtenberg, Attorney-in-Fact
Issuer symbol
KALA
Transactions as of
04 Jan 2023
Transactions value $
$0
Form type
4
Filing time
06 Jan 2023, 19:00:38 UTC
Previous filing
17 Nov 2021
Next filing
02 Jun 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KALA Common Stock Award $0 +9,525 +161% $0 15,439 04 Jan 2023 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Grant of restricted stock units ("RSUs") under the Issuer's 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the Reporting Person's continued employment with Issuer, the RSUs will vest as to 1/3 of the shares underlying the RSUs on January 4, 2024, as to 1/3 of the shares underlying the RSUs on January 4, 2025 and as to the final 1/3 of shares underlying the RSUs on January 4, 2026.
F2 Includes 9,525 unvested RSUs and 1,294 shares of the Issuer's common stock issuable to the Reporting Person in connection with the Issuer's acquisition of Combangio, Inc. and which are being held back by the Issuer until February 15, 2023 as partial security for the satisfaction of indemnification obligations and other payment obligations of the former Combangio equityholders.
F3 The number of shares of common stock reported on this Form 4 reflects a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022.